Prospective Pilot Study of Plasma Cell–Targeted Therapy With Bortezomib in Refractory IgA Nephropathy
Short course bortezomib therapy led to sustained proteinuria reduction in patients with IgAN, with an acceptable safety profile. These results support further evaluation in larger, controlled trials.
Authors
- Jingyuan Xie (ORCID: https://orcid.org/0000-0002-5508-0664)
- Hong Ren
- Li Xiao (ORCID: https://orcid.org/0000-0002-3627-2513)
- Lin Li (ORCID: https://orcid.org/0000-0003-3178-1850)
- Nan Chen (ORCID: https://orcid.org/0000-0001-9825-2369)
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1016/j.ekir.2025.06.006
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- NIH Clinical Center